BIA Separations strike partnership with Labena d.o.o., one of the providers of solutions for process and laboratory analytics in the area of South Eastern Europe.
“BIA Separations’ main focus has always been products for manufacturing of biological drugs, viral vectors, vaccines. The gene therapy market started to grow exponentially within the last year and the demand for our services greatly increased, so we have decided to put all our efforts here”, said Ales Strancar.
“This has driven our decision to enter into a partnership with Labena which will begin to distribute BIA Separations products in the area of South Eastern Europe. In addition, the CRO laboratory, which offers services for pharmaceutical companies providing generic drugs and smaller molecules, will continue its activities within Labena group of companies. This will allow the CRO laboratory to expand its customers portfolio and improve the service and support to their customers”, Strancar added.
“We are very pleased that we have managed to come up with a mutual agreement with BIA Separations about the takeover of the CRO laboratory of BIA Separation which is one of the most recognized and renowned in the region. Adding a CRO Laboratory with GMP certificate and FDA audit report to Labena Group will have many beneficial effects for our business model and the services provided by the CRO Laboratory in the South East Europe. We see this also as opportunity to expand our business outside our region to other countries of EU zone. Our plan is to invest into further development of activities and services of the CRO Laboratory not only in equipment and manpower, but more important in expanding of services to suitability studies and genetic research for pharmaceutical industry” said Borut Ceh CEO of Labena.